Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

BACKGROUND: Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for...

Descripción completa

Detalles Bibliográficos
Autores principales: Auclin, Edouard, André, Thierry, Taieb, Julien, Banzi, Maria, Van Laethem, Jean-Luc, Tabernero, Josep, Hickish, Tamas, de Gramont, Aimery, Vernerey, Dewi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738041/
https://www.ncbi.nlm.nih.gov/pubmed/31296923
http://dx.doi.org/10.1038/s41416-019-0521-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738041/
https://www.ncbi.nlm.nih.gov/pubmed/31296923
http://dx.doi.org/10.1038/s41416-019-0521-7

Ejemplares similares